januxrx.com (JANX): Rasio rega marang prakiraan pendapatan

JANX (Janux Therapeutics Inc) - tandha merek perusahaan

Janux Therapeutics (JANX) relies on a flexible research environment and a strong team of immunologists. The forward price-to-sales valuation trend confirms market interest in their "smart" molecules that act strictly within tumors. Positive prostate cancer test data create a bullish backdrop, while 29.80 determines the current status of the parameter, capturing investor expectations ahead of the start of phase II trials.

JANX Janux Therapeutics Inc: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 16.11.2026

Rincian analitis perusahaan Janux Therapeutics (JANX)

Ringkesan analisis perusahaan:januxrx.com JANX
Produk sing diprodhuksi Janux Corp

Investors assess business resilience through the ratio of market value to expected cash flows. This indicator compares current capitalization with projected revenue, revealing the actual balance of demand for each trading session. For Janux Therapeutics (JANX), this is critical, as the value of smart cancer therapy drugs is priced into market expectations a priori. By analyzing the projected P/S dynamics, one can promptly identify a loss of momentum and avoid deep drawdowns.

Analisis pesaing

ImmunityBio Inc - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Corp IMCR|RCUS - Rasio rega marang prakiraan pendapatan|ZYME (zymeworks.com) - Kapitalisasi marang prakiraan pendapatan|Tango Therapeutics Corp (TNGX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Iovance (IOVA)|Multiplikator forward rega marang pendapatan IMTX|XNCR - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan CMPX (Compass Bio)|Rasio rega marang pendapatan sing dikarepake REPL|Multiplikator Forward P/S LYEL (Lyell Immunopharma, Inc.)|Rega forward marang dodolan IPHA|Pyxis - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Compugen|IO Biotech, Inc. (IOBT) - Rasio rega marang prakiraan pendapatan|Sutro Biopharma, Inc. - Rega forward marang dodolan|INKT (minktherapeutics.com) - Multiplikator Forward P/S|Multiplikator Forward P/S werewolftx.com|Rasio rega marang prakiraan pendapatan immixbio.com (IMMX)|ALXO: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S CUE (Cue Biopharma Inc.)|PDS Biotechnology (PDSB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SONN - Rasio rega marang prakiraan pendapatan|MAIA Biotechnology, Inc. (MAIA) - Multiplikator forward rega marang pendapatan|LIMN: Multiplikator Forward P/S|LAVA Therapeutics N.V. (LVTX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan NXTC|Multiplikator Forward P/S leaptx.com|Multiplikator Forward P/S INTS|Rasio kapitalisasi marang dodolan sing dikarepake Sensei Biotherapeutics, Inc.|Multiplikator Forward P/S TOVX (Theriva Corp)|Rasio kapitalisasi marang dodolan sing dikarepake gritstonebio.com (GRTS)|kinetabio.com - Multiplikator Forward P/S|NexImmune (NEXI) - Multiplikator forward rega marang pendapatan|turnstonebio.com (TSBX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vaccinex, Inc (VCNX)|Multiplikator forward rega marang pendapatan HARP